| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | -0.0084 | 0.9 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |